Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the first line of treatment. A fundamental aspect is activation and platelet aggregation, which is why, in addition to creating networks to optimize STEMI treatment, prehospital drug treatments have been implemented.  The COMPARECrush looked at whether early and powerful<a href="https://solaci.org/en/2024/07/08/prehospital-crushed-vs-integral-prasugrel-in-stemi-patients-with-large-myocardial-area-at-risk/" title="Read more" >...</a>

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Secondary Prevention with P2Y12 Inhibitors: How Consolidated Is This Long Term Alternative vs. Aspirin?

Secondary prevention with P2Y12 inhibitors vs aspirin monotherapy in CAD patients Antiaggregation therapy plays a central role at long term to prevent new cardiovascular events in atherosclerosis patients.  After repeat myocardial infarction (MI) or stroke, prognosis can vary considerably. Even though the current guidelines prefer aspirin as the first choice for secondary prevention over P2Y12<a href="https://solaci.org/en/2023/07/13/secondary-prevention-with-p2y12-inhibitors-how-consolidated-is-this-long-term-alternative-vs-aspirin/" title="Read more" >...</a>

Aspirina o clopidogrel post TAVI: Guías y estudios llenos de contradicciones

Is Clopidogrel Monotherapy Safe After a Month of Dual Antiplatelet Therapy in Diabetic Patients?

Currently, many randomized studies have suggested that short-term dual antiplatelet therapy (DAPT) followed by monotherapy reduces bleeding without increasing major cardiovascular events after percutaneous coronary intervention (PCI). A meta-analysis of six randomized studies has shown this benefit using ticagrelor monotherapy after short DAPT. However, there is no data on the results of clopidogrel monotherapy. Researchers<a href="https://solaci.org/en/2022/12/27/is-clopidogrel-monotherapy-safe-after-a-month-of-dual-antiplatelet-therapy-in-diabetic-patients/" title="Read more" >...</a>

P2Y12 Inhibitor Monotherapy vs Aspirin: Results of a Network Meta-Analysis

Revascularization and antiaggregation guidelines have typically recommended aspirin (AAS) as first choice for secondary prevention of cardiovascular events after DES stenting. However, these past few years this strategy has been called into question, seeing as studies have shown the superiority of P2Y12 inhibitor monotherapy (IP2Y12) with clopidogrel or ticagrelor. There is little data comparing both<a href="https://solaci.org/en/2022/12/05/p2y12-inhibitor-monotherapy-vs-aspirin-results-of-a-network-meta-analysis/" title="Read more" >...</a>

Jornadas Paraguay: Concurso de Jóvenes Cardiólogos

Watch the Highlighted Presentations of the Paraguay Sessions 2022

The 44th SOLACI Regional Sessions – 15th South Cone Region took place in a hybrid setting (F2F and online) in Asuncion, Paraguay, between June 30 and July 1, 2022. It was a successful event that featured prestigious national and international guests and a world class scientific program.  Next, we share some of the presentations held<a href="https://solaci.org/en/2022/09/14/watch-the-highlighted-presentations-of-the-paraguay-sessions-2022/" title="Read more" >...</a>

¿Llegó el momento de replantear a la aspirina como la elección en prevención secundaria de MACE?

Should Aspirin Be the Standard of Secondary Prevention of MACE?

Much has been published recently on short term dual antiplatelet therapy (DAPT) both in acute (ACS) and chronic coronary syndrome (CCS) as well as safety of P2Y12 inhibitor monotherapy. When discussing secondary prevention in patients with established coronary artery disease, aspirin (ASA) has been the preferred drug for the prevention of new atherothrombotic events.  This<a href="https://solaci.org/en/2022/04/27/should-aspirin-be-the-standard-of-secondary-prevention-of-mace/" title="Read more" >...</a>

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

HOST-EXAM: The Study that Challenges Aspirin as Long-Term Antiplatelet Therapy

The HOST-EXAM study (which was prospective, randomized, and open-label, with the participation of 37 Korean sites) was specifically designed to determine the role of aspirin as the long-term antiplatelet therapy of choice after angioplasty with current drug-eluting stents. To this end, the study compared aspirin head-to-head with clopidogrel. Over the course of four years, 5438 patients (mean<a href="https://solaci.org/en/2021/09/10/host-exam-the-study-that-challenges-aspirin-as-long-term-antiplatelet-therapy/" title="Read more" >...</a>

The Role of Aspirin after the TWILIGHT-ACS

This analysis corroborates the potential benefit of ticagrelor monotherapy following a short period of dual antiaggregation (DAPT) in patients with acute coronary syndrome (ACS). This benefit consists of a significant bleeding reduction (3.6% vs. 7.6%, P < 0.001), without compromising ischemic events (4.3% vs. 4.4%, P = 0.84). The latter, however, could be seen as<a href="https://solaci.org/en/2021/08/10/the-role-of-aspirin-after-the-twilight-acs/" title="Read more" >...</a>

Es posible esterilizar las máscaras N95 y los barbijos quirúrgicos

Primary COVID-19 Infection Protects Against Potential Reinfection?

These study outcomes suggest reinfection is relatively rare in patients who recover from COVID-19. In addition, natural immunity against SARS-CoV-2 persists for at least one year and offers similar protection to that reported by vaccines.   These data were obtained from cases infected with the original virus. For now, we do not know if it also<a href="https://solaci.org/en/2021/06/08/primary-covid-19-infection-protects-against-potential-reinfection/" title="Read more" >...</a>

ACC 2021 | ADAPTABLE: Bajas dosis de aspirina son iguales de efectivas y con muy bajo riesgo de sangrado

ACC 2021 | ADAPTABLE: Low Doses of Aspirin Are Equally Effective and Present Lower Bleeding Risk

Patients diagnosed with cardiovascular disease taking aspirin as secondary prevention can take lower doses and achieve the same efficacy level as those taking 325 mg. According to the ADAPTABLE study, presented at the American College of Cardiology (ACC) 2021 Congress and simultaneously published in the New England Journal of Medicine (NEJM), both schemes were associated with<a href="https://solaci.org/en/2021/05/18/acc-2021-adaptable-low-doses-of-aspirin-are-equally-effective-and-present-lower-bleeding-risk/" title="Read more" >...</a>

aspirina